Analysis and Commentary STEVEN GROSSMAN 3/15/24 Analysis and Commentary STEVEN GROSSMAN 3/15/24 Q&A About FDA Funding in FY 24 and FY 25 Read More Advocacy at a Glance STEVEN GROSSMAN 3/13/24 Advocacy at a Glance STEVEN GROSSMAN 3/13/24 Special Edition: Alliance Responds to President’s FY25 Budget Read More Advocacy at a Glance STEVEN GROSSMAN 3/8/24 Advocacy at a Glance STEVEN GROSSMAN 3/8/24 House Passes Agriculture/FDA Appropriations Bill Providing Full Year Funding - Senate Action Pending Read More Analysis and Commentary STEVEN GROSSMAN 3/8/24 Analysis and Commentary STEVEN GROSSMAN 3/8/24 Looking Ahead to the President’s FY25 Budget Request Read More Advocacy at a Glance STEVEN GROSSMAN 3/1/24 Advocacy at a Glance STEVEN GROSSMAN 3/1/24 Continuing Resolution Extended with Final Action on Agriculture/FDA Expected Next Week Read More Analysis and Commentary STEVEN GROSSMAN 3/1/24 Analysis and Commentary STEVEN GROSSMAN 3/1/24 Budget Angles: “Not All User Fees Are Alike” and “No Base, No Clarity” Read More Advocacy at a Glance STEVEN GROSSMAN 2/23/24 Advocacy at a Glance STEVEN GROSSMAN 2/23/24 FY 24 Agriculture/FDA Appropriations Bill May - or May Not - Move by March 1 Read More Analysis and Commentary STEVEN GROSSMAN 2/23/24 Analysis and Commentary STEVEN GROSSMAN 2/23/24 5 Things to Know About the FY 24 Appropriations Endgame Read More Advocacy at a Glance STEVEN GROSSMAN 2/16/24 Advocacy at a Glance STEVEN GROSSMAN 2/16/24 FY 2024 Agriculture/FDA Funding–Remaining Issues Read More Analysis and Commentary STEVEN GROSSMAN 2/16/24 Analysis and Commentary STEVEN GROSSMAN 2/16/24 Urging Members of Congress to Request Strong FDA Funding for FY 2025 Read More Advocacy at a Glance STEVEN GROSSMAN 2/9/24 Advocacy at a Glance STEVEN GROSSMAN 2/9/24 Overall Appropriations Prospects: Murky with a Chance of Progress Read More Analysis and Commentary STEVEN GROSSMAN 2/9/24 Analysis and Commentary STEVEN GROSSMAN 2/9/24 Developing the Alliance’s FY 2025 Recommendations Read More Advocacy at a Glance STEVEN GROSSMAN 2/2/24 Advocacy at a Glance STEVEN GROSSMAN 2/2/24 Negotiations on Final Agriculture/FDA Appropriations Bill Moving Ahead Read More Analysis and Commentary STEVEN GROSSMAN 2/2/24 Analysis and Commentary STEVEN GROSSMAN 2/2/24 FY 24 Funding Is Not Settled; Yet FY 25 Is Coming Soon Read More Advocacy at a Glance STEVEN GROSSMAN 1/26/24 Advocacy at a Glance STEVEN GROSSMAN 1/26/24 What Comes Next in the Congressional Process Read More Analysis and Commentary STEVEN GROSSMAN 1/26/24 Analysis and Commentary STEVEN GROSSMAN 1/26/24 Status of FY 24 and FY 25 Funding for FDA: Addressing Some FAQs Read More Advocacy at a Glance STEVEN GROSSMAN 1/19/24 Advocacy at a Glance STEVEN GROSSMAN 1/19/24 Senate and House Approve 6-week Continuing Resolution Avoiding a Shutdown Read More Advocacy at a Glance STEVEN GROSSMAN 1/12/24 Advocacy at a Glance STEVEN GROSSMAN 1/12/24 FY 24: No Certainty on What Comes Next Read More Analysis and Commentary STEVEN GROSSMAN 1/12/24 Analysis and Commentary STEVEN GROSSMAN 1/12/24 What Happens to FDA If There is a Shutdown Read More Advocacy at a Glance STEVEN GROSSMAN 1/5/24 Advocacy at a Glance STEVEN GROSSMAN 1/5/24 FDA In First Tranche of Agencies Whose CR Expires on January 19 Read More Newer Posts Older Posts
Analysis and Commentary STEVEN GROSSMAN 3/15/24 Analysis and Commentary STEVEN GROSSMAN 3/15/24 Q&A About FDA Funding in FY 24 and FY 25 Read More
Advocacy at a Glance STEVEN GROSSMAN 3/13/24 Advocacy at a Glance STEVEN GROSSMAN 3/13/24 Special Edition: Alliance Responds to President’s FY25 Budget Read More
Advocacy at a Glance STEVEN GROSSMAN 3/8/24 Advocacy at a Glance STEVEN GROSSMAN 3/8/24 House Passes Agriculture/FDA Appropriations Bill Providing Full Year Funding - Senate Action Pending Read More
Analysis and Commentary STEVEN GROSSMAN 3/8/24 Analysis and Commentary STEVEN GROSSMAN 3/8/24 Looking Ahead to the President’s FY25 Budget Request Read More
Advocacy at a Glance STEVEN GROSSMAN 3/1/24 Advocacy at a Glance STEVEN GROSSMAN 3/1/24 Continuing Resolution Extended with Final Action on Agriculture/FDA Expected Next Week Read More
Analysis and Commentary STEVEN GROSSMAN 3/1/24 Analysis and Commentary STEVEN GROSSMAN 3/1/24 Budget Angles: “Not All User Fees Are Alike” and “No Base, No Clarity” Read More
Advocacy at a Glance STEVEN GROSSMAN 2/23/24 Advocacy at a Glance STEVEN GROSSMAN 2/23/24 FY 24 Agriculture/FDA Appropriations Bill May - or May Not - Move by March 1 Read More
Analysis and Commentary STEVEN GROSSMAN 2/23/24 Analysis and Commentary STEVEN GROSSMAN 2/23/24 5 Things to Know About the FY 24 Appropriations Endgame Read More
Advocacy at a Glance STEVEN GROSSMAN 2/16/24 Advocacy at a Glance STEVEN GROSSMAN 2/16/24 FY 2024 Agriculture/FDA Funding–Remaining Issues Read More
Analysis and Commentary STEVEN GROSSMAN 2/16/24 Analysis and Commentary STEVEN GROSSMAN 2/16/24 Urging Members of Congress to Request Strong FDA Funding for FY 2025 Read More
Advocacy at a Glance STEVEN GROSSMAN 2/9/24 Advocacy at a Glance STEVEN GROSSMAN 2/9/24 Overall Appropriations Prospects: Murky with a Chance of Progress Read More
Analysis and Commentary STEVEN GROSSMAN 2/9/24 Analysis and Commentary STEVEN GROSSMAN 2/9/24 Developing the Alliance’s FY 2025 Recommendations Read More
Advocacy at a Glance STEVEN GROSSMAN 2/2/24 Advocacy at a Glance STEVEN GROSSMAN 2/2/24 Negotiations on Final Agriculture/FDA Appropriations Bill Moving Ahead Read More
Analysis and Commentary STEVEN GROSSMAN 2/2/24 Analysis and Commentary STEVEN GROSSMAN 2/2/24 FY 24 Funding Is Not Settled; Yet FY 25 Is Coming Soon Read More
Advocacy at a Glance STEVEN GROSSMAN 1/26/24 Advocacy at a Glance STEVEN GROSSMAN 1/26/24 What Comes Next in the Congressional Process Read More
Analysis and Commentary STEVEN GROSSMAN 1/26/24 Analysis and Commentary STEVEN GROSSMAN 1/26/24 Status of FY 24 and FY 25 Funding for FDA: Addressing Some FAQs Read More
Advocacy at a Glance STEVEN GROSSMAN 1/19/24 Advocacy at a Glance STEVEN GROSSMAN 1/19/24 Senate and House Approve 6-week Continuing Resolution Avoiding a Shutdown Read More
Advocacy at a Glance STEVEN GROSSMAN 1/12/24 Advocacy at a Glance STEVEN GROSSMAN 1/12/24 FY 24: No Certainty on What Comes Next Read More
Analysis and Commentary STEVEN GROSSMAN 1/12/24 Analysis and Commentary STEVEN GROSSMAN 1/12/24 What Happens to FDA If There is a Shutdown Read More
Advocacy at a Glance STEVEN GROSSMAN 1/5/24 Advocacy at a Glance STEVEN GROSSMAN 1/5/24 FDA In First Tranche of Agencies Whose CR Expires on January 19 Read More
